Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice
- PMID: 29023811
- DOI: 10.1002/hep.29579
Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice
Abstract
Hepatopulmonary syndrome (HPS) is a severe complication of cirrhosis with increased risk of mortality. Pulmonary microvascular alterations are key features of HPS; but underlying mechanisms are incompletely understood, and studies on HPS are limited to rats. Placental growth factor (PlGF), a proangiogenic molecule that is selectively involved in pathological angiogenesis, may play an important role in HPS development; however, its role has never been investigated. In this study, we validated an HPS model by common bile duct ligation (CBDL) in mice, investigated the kinetic changes in pulmonary angiogenesis and inflammation during HPS development, and provide evidence for a novel therapeutic strategy by targeting pathological angiogenesis. Mice with CBDL developed hypoxemia and intrapulmonary shunting on a background of liver fibrosis. Pulmonary alterations included increased levels of proangiogenic and inflammatory markers, which was confirmed in serum of human HPS patients. Increased PlGF production in HPS mice originated from alveolar type II cells and lung macrophages, as demonstrated by immunofluorescent staining. Dysfunctional vessel formation in CBDL mice was visualized by microscopy on vascular corrosion casts. Both prophylactic and therapeutic anti-PlGF (αPlGF) antibody treatment impeded HPS development, as demonstrated by significantly less intrapulmonary shunting and improved gas exchange. αPlGF treatment decreased endothelial cell dysfunction in vivo and in vitro and was accompanied by reduced pulmonary inflammation. Importantly, αPlGF therapy did not affect liver alterations, supporting αPlGF's ability to directly target the pulmonary compartment.
Conclusion: CBDL in mice induces HPS, which is mediated by PlGF production; αPlGF treatment improves experimental HPS by counteracting pulmonary angiogenesis and might be an attractive therapeutic strategy for human HPS. (Hepatology 2017).
© 2017 by the American Association for the Study of Liver Diseases.
Comment in
-
Placental growth factor: New treatment target bringing hope for hepatopulmonary syndrome.Hepatology. 2018 Aug;68(2):404-407. doi: 10.1002/hep.29795. Epub 2018 May 14. Hepatology. 2018. PMID: 29356037 No abstract available.
Similar articles
-
Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.Hepatology. 2018 Nov;68(5):2016-2028. doi: 10.1002/hep.30079. Hepatology. 2018. PMID: 29729196 Free PMC article. Review.
-
The role of CX₃CL1/CX₃CR1 in pulmonary angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome.J Hepatol. 2012 Oct;57(4):752-8. doi: 10.1016/j.jhep.2012.05.014. Epub 2012 May 29. J Hepatol. 2012. PMID: 22659346 Free PMC article.
-
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G72-80. doi: 10.1152/ajpgi.00178.2013. Epub 2013 Nov 7. Am J Physiol Gastrointest Liver Physiol. 2014. PMID: 24200956 Free PMC article.
-
CXCR2 is involved in pulmonary intravascular macrophage accumulation and angiogenesis in a rat model of hepatopulmonary syndrome.Clin Sci (Lond). 2017 Jan 1;131(2):159-168. doi: 10.1042/CS20160593. Epub 2016 Nov 22. Clin Sci (Lond). 2017. PMID: 27879294
-
Hepatopulmonary syndrome: update on pathogenesis and clinical features.Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):539-49. doi: 10.1038/nrgastro.2012.123. Epub 2012 Jul 3. Nat Rev Gastroenterol Hepatol. 2012. PMID: 22751459 Free PMC article. Review.
Cited by
-
Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.Hepatology. 2018 Nov;68(5):2016-2028. doi: 10.1002/hep.30079. Hepatology. 2018. PMID: 29729196 Free PMC article. Review.
-
Hepatopulmonary syndrome.JHEP Rep. 2022 Jul 4;4(9):100527. doi: 10.1016/j.jhepr.2022.100527. eCollection 2022 Sep. JHEP Rep. 2022. PMID: 36035361 Free PMC article. Review.
-
Krüppel-like factor 6 mediates pulmonary angiogenesis in rat experimental hepatopulmonary syndrome and is aggravated by bone morphogenetic protein 9.Biol Open. 2019 Jun 26;8(6):bio040121. doi: 10.1242/bio.040121. Biol Open. 2019. PMID: 31189661 Free PMC article.
-
Hepatocyte-derived exosomal MiR-194 activates PMVECs and promotes angiogenesis in hepatopulmonary syndrome.Cell Death Dis. 2019 Nov 7;10(11):853. doi: 10.1038/s41419-019-2087-y. Cell Death Dis. 2019. PMID: 31700002 Free PMC article.
-
Lipocalin-2 Secreted by the Liver Regulates Neuronal Cell Function Through AKT-Dependent Signaling in Hepatic Encephalopathy Mouse Model.Clin Nutr Res. 2023 Apr 26;12(2):154-167. doi: 10.7762/cnr.2023.12.2.154. eCollection 2023 Apr. Clin Nutr Res. 2023. PMID: 37214781 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources